Patents Assigned to Merck
  • UREA OREXIN RECEPTOR AGONISTS
    Publication number: 20240101555
    Abstract: The present invention is directed to urea compounds which are agonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.
    Type: Application
    Filed: December 14, 2021
    Publication date: March 28, 2024
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Kira A. Armacost, Maria Irina Chiriac, Danielle M. Hurzy, Jeffrey C. Kern, Jian Liu, Peter J. Manley, Philippe Nantermet, Vanessa L. Rada, Michael T. Rudd, Craig A. Stump
  • HUMAN INTERLEUKIN-2 CONJUGATES BIASED FOR THE INTERLEUKIN-2 RECEPTOR BETA-GAMMAC DIMER AND CONJUGATED TO A NONPEPTIDIC, WATER-SOLUBLE POLYMER
    Publication number: 20240101631
    Abstract: Interleukin-2 (IL-2) conjugates comprising at least one or more amino acid substitutions that bias binding to the IL-2 receptor ??c dimer over binding the IL-2 receptor ???c trimer and a non-natural amino acid at or near the N-terminus conjugated to a water-soluble polymer are described. The IL-2 conjugates are useful for treatment and prevention of cell proliferation and cancer in a patient.
    Type: Application
    Filed: October 11, 2023
    Publication date: March 28, 2024
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Cristina Abrahams, Edward Bowman, Xiaofan Li, Songnian Lin, Willy Solis, Ryan Stafford, Aarron Willingham, Alice Yam, Junhao Yang, Gang Yin
  • Materials for organic electroluminescent devices
    Patent number: 11939339
    Abstract: The present invention relates to compounds of the formula (1) which are suitable for use in electronic devices, in particular organic electroluminescent devices, and to electronic devices which comprise these compounds.
    Type: Grant
    Filed: November 22, 2018
    Date of Patent: March 26, 2024
    Assignee: Merck Patent GmbH
    Inventors: Rouven Linge, Sebastian Meyer, Aaron Lackner, Holger Heil, Nils Koenen
  • Liquid crystal mixture and liquid crystal display
    Patent number: 11939511
    Abstract: The invention relates to a compound of formula I, wherein R11, R21, A11, A, Z, X11, X21, Y11, Y12, Sp11, Sp21, o and p have one of the meanings as given in claim 1. The invention further relates to method of production of a compound of formula I, to the use of said compounds in LC media and to LC media comprising one or more compounds of formula I. Further, the invention relates to a method of production of such LC media, to the use of such media in LC devices, and to LC device comprising a LC medium according to the present invention. The present invention further relates to a process for the fabrication such liquid crystal display and to the use of the liquid crystal mixtures according to the invention for the fabrication of such liquid crystal display.
    Type: Grant
    Filed: April 18, 2019
    Date of Patent: March 26, 2024
    Assignee: MERCK PATENT GMBH
    Inventors: Lars Lietzau, Simon Siemianowski, Izumi Saito
  • Vent filter and pure liquid storage tank
    Patent number: 11938436
    Abstract: A vent filter (1), preferably for a pure liquid storage tank, comprising a cylindrical shell (2), at least one compartment (A) for accommodating granular filter material (3), said at least one compartment (A) defined between an inner peripheral surface (4) of the shell (2) and a pair of spaced apart separator plates (5) arranged in the shell (2) such that the spacing of the separator plates (5) in the axial direction of the shell (2) can be changed and fixed so as to apply a pressure on the granular filter material (3) in the at least one compartment (A). An air inlet (6) and an air outlet (7) are respectively arranged to allow a flow of air through the granular filter material (3) in the at least one compartment (A).
    Type: Grant
    Filed: September 5, 2019
    Date of Patent: March 26, 2024
    Assignee: Merck Patent GmbH
    Inventor: Christian Berducat
  • Dichroic dye composition
    Patent number: 11939512
    Abstract: The present invention relates to compositions comprising a combination of benzothiadiazole and thiadiazoloquinoxaline derivatives, to liquid-crystalline media containing the compositions, and to the use of the compositions and the media in optical, electronic and electro-optical devices, in particular in devices for regulating the passage of energy from an outside space into an inside space, for example in switchable windows.
    Type: Grant
    Filed: November 21, 2019
    Date of Patent: March 26, 2024
    Assignee: Merck Patent GmbH
    Inventors: Michael Junge, Ewa Ptak, Christoph Wetzel
  • Liquid-crystalline medium
    Patent number: 11939509
    Abstract: A liquid-crystalline medium which comprises at least one compound selected from the group of compounds of the formulae IA to IH, in which Z1 denotes a single bond, —CH2CH2—, —CH?CH—, —CH2O—, —OCH2—, —CF2O—, —OCF2—, —COO—, —OCO—, —C2F4—, —(CH2)4—, —CHFCHF—, —CF2CH2—, —CH2CF2—, —C?C—, —CF?CF—, —CH?CHCHO— or —CH2CF2O—, and the use thereof for an active-matrix display, in particular based on the VA, PSA, PS-VA, PALC, FFS, PS-FFS, SA-VA, PS-IPS or IPS effect.
    Type: Grant
    Filed: February 3, 2021
    Date of Patent: March 26, 2024
    Assignee: MERCK PATENT GMBH
    Inventors: Harald Hirschmann, Monika Bauer, Martina Windhorst, Marcus Reuter, Kristin Weiss
  • Polymerisable liquid crystal material and polymerised liquid crystal film
    Patent number: 11939510
    Abstract: The invention relates to a polymerisable LC material comprising at least one di- or multireactive mesogenic compound of formula T, RT1-(AT1ZT1)m1-GT1-(ZT2-AT2)m2-RT2??T and at least one compound of formula CO-1, wherein the parameter are RT1, AT1, ZT1, m1, GT1, ZT2, AT2, m2, RT2, L1 to L3, R1 and R2, and n are defined as given in claim 1. Furthermore, the present invention relates also to a method for its preparation, a polymer film with improved thermal durability obtainable from the corresponding polymerisable LC material, to a method of preparation of such polymer film, and to the use of such polymer film and said polymerisable LC material for optical, electro-optical, decorative or security devices.
    Type: Grant
    Filed: August 13, 2018
    Date of Patent: March 26, 2024
    Assignee: MERCK PATENT GMBH
    Inventors: Eduardo Beltran Gracia, Kevin Adlem, Naomi Weare, Hassan Norouzi-Arasi
  • Quinolin-2-one derivatives
    Patent number: 11939314
    Abstract: Compounds of the formula I in which X1, X2, X3, X4, R1, R2, R3, Q and Y have the meanings indicated in claim 1, are inhibitors of c-Kit kinase, and can be employed for the treatment of cancer.
    Type: Grant
    Filed: October 12, 2021
    Date of Patent: March 26, 2024
    Assignee: MERCK PATENT GMBH
    Inventors: Dieter Dorsch, Mathilde Muzerelle, Lars Burgdorf, Margarita Wucherer-Plietker, Paul Czodrowski, Christina Esdar, Christos Tsaklakidis
  • POLYSILAZANE HARD COATING COMPOSITIONS
    Publication number: 20240093058
    Abstract: The present invention relates to coating compositions which comprise a silazane polymer (A), a silane coupling agent (B); and inorganic nanoparticles (C), wherein the components (A), (B) and (C) are present in certain ratios. The coating compositions are particularly suitable for the preparation of hard coatings on surfaces of various base material substrates.
    Type: Application
    Filed: January 5, 2022
    Publication date: March 21, 2024
    Applicant: MERCK PATENT GMBH
    Inventors: Ralf GROTTENMUELLER, Sergej NELL, Patrizia LACHNIT, Thomas KRASEMANN
  • METHODS FOR TREATING CANCER OR INFECTION USING A COMBINATION OF AN ANTI-PD-1 ANTIBODY, AN ANTI-LAG3 ANTIBODY, AND AN ANTI-TIGIT ANTIBODY
    Publication number: 20240092902
    Abstract: Provided herein are methods of treating cancer or infection, which comprise administering to a human patient in need thereof: (a) an anti-human PD-1 monoclonal antibody or antigen binding fragment thereof; (b) an anti-human LAG3 monoclonal antibody or antigen binding fragment thereof; and (c) an anti-human TIGIT monoclonal antibody or antigen binding fragment thereof. Also provided are pharmaceutical compositions and kits containing such agents for the treatment of cancer or infection.
    Type: Application
    Filed: September 6, 2023
    Publication date: March 21, 2024
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Mingmei Cai, Rene de Waal Malefyt, Laurence Fayadat-Dilman, Ying Li, Ruban Mangadu, Uyen Phan
  • SYNTHESIS OF ANTIVIRAL NUCLEOSIDES
    Publication number: 20240092818
    Abstract: The present invention relates to efficient synthetic processes useful in the preparation of antiviral nucleosides, particularly uridine 4-oxime 5?-(2-methylpropanoate) {(2R,3S,4R,5R)-3,4-dihydroxy-5-[4-(hydroxyimino)-2-oxo-3,4-dihydropyrimidin-1(2H)-yl]oxolan-2-yl}methyl 2-methylpropanoate and pharmaceutically acceptable salts, derivatives, tautomers, isomers, and prodrugs of, which may be active as antiviral agents, as well as compositions and methods thereof. The present invention also encompasses intermediates useful in the disclosed synthetic processes and the methods of their preparation.
    Type: Application
    Filed: December 17, 2021
    Publication date: March 21, 2024
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Tamas Benkovics, Patrick S. Fier, Anna Fryszkowska, Mark A. Huffman, Tetsuji Itoh, Jongrock Kong, Peter E. Maligres, Kevin M. Maloney, John McIntosh, Grant S. Murphy, Steven M. Silverman, Hao Yang
  • Liquid-crystalline medium
    Patent number: 11932797
    Abstract: A liquid-crystalline medium which comprises at least one compound selected from the group of compounds of the formulae IA to IH, in which Z1 denotes a single bond, —CH2CH2—, —CH?CH—, —CH2O—, —OCH2—, —CF2O—, —OCF2—, —COO—, —OCO—, —C2F4—, —(CH2)4—, —CHFCHF—, —CF2CH2—, —CH2CF2—, —C?C—, —CF?CF—, —CH?CHCHO— or —CH2CF2O—, and the use thereof for an active-matrix display, in particular based on the VA, PSA, PS-VA, PALC, FFS, PS-FFS, SA-VA, PS-IPS or IPS effect.
    Type: Grant
    Filed: January 29, 2021
    Date of Patent: March 19, 2024
    Assignee: MERCK PATENT GMBH
    Inventors: Harald Hirschmann, Monika Bauer, Martina Windhorst, Marcus Reuter, Kristin Weiss
  • Cyclic polypeptides for PCSK9 inhibition
    Patent number: 11932705
    Abstract: Provided herein are cyclic polypeptide compounds that can, e.g., bind specifically to human proprotein convertase subtilisin/kexin type 9 (PCSK9) and optionally also inhibit interaction between human PCSK9 and human low density lipoprotein receptor (LDLR), and pharmaceutical compositions comprising one or more of these compounds. Also provided are methods of reducing LDL cholesterol level in a subject in need thereof that include administering to the subject one or more of the cyclic polypeptide compounds or a pharmaceutical composition provided herein.
    Type: Grant
    Filed: August 29, 2022
    Date of Patent: March 19, 2024
    Assignees: MERCK SHARP & DOHME LLC, RA PHARMACEUTICALS, INC.
    Inventors: Alonso Ricardo, Thomas Joseph Tucker, Nicolas Cedric Boyer, Ketki Ashok Dhamnaskar, Zhong Ma, Angela Dawn Kerekes, Chengwei Wu, Sookhee Nicole Ha, Hyewon Youm, Elisabetta Bianchi, Danila Branca, Raffaele Ingenito, Willy Costantini, Aurash Shahripour, Yusheng Xiong
  • Chromane amidine monobactam compounds for the treatment of bacterial infections
    Patent number: 11932637
    Abstract: The present invention relates to monobactam compounds of Formula I: and pharmaceutically acceptable salts thereof. The present invention also relates to compositions which comprise a monobactam compound of structural formula I or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. The invention further relates to methods for treating a bacterial infection comprising administering to the patient a therapeutically effective amount of a compound of structural formula I, either alone or in combination with a therapeutically effective amount of a second beta-lactam antibiotic.
    Type: Grant
    Filed: November 16, 2022
    Date of Patent: March 19, 2024
    Assignee: Merck Sharp & Dohme LLC
    Inventors: Helen Y. Chen, Shuzhi Dong, Zhiyong Hu, Jing Su, Tao Yu, Yong Zhang
  • AMIDO-SUBSTITUTED PYRIDYL COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF HERPESVIRUSES
    Publication number: 20240083910
    Abstract: The present invention relates to novel Amido-Substituted Heterocycle Compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, and R5 are as defined herein. The present invention also relates to compositions comprising at least one Amido-Substituted Heterocycle Compounds for treating or preventing a herpesvirus infection in a patient.
    Type: Application
    Filed: December 14, 2021
    Publication date: March 14, 2024
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Richard Thaddeus Berger, JR., Christopher Douglas Cox, Brendan M. Crowley, Marc Labroli, Michael Aaron Plotkin, Izzat Tiedje Raheem, Deyou Sha, Anthony W. Shaw, Jason W. Skudlarek, Ling Tong
  • ARYL ETHER COMPOUNDS AS TEAD MODULATORS
    Publication number: 20240083903
    Abstract: The present invention is directed to a compound of Formula I: or a pharmaceutically acceptable salt thereof, as well as pharmaceutical compositions comprising them and methods of using such compounds or pharmaceutical salts thereof.
    Type: Application
    Filed: February 15, 2022
    Publication date: March 14, 2024
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Jongwon Lim, Vladimir Simov, Brandon A. Vara, Charles S. Yeung, Sebastian E. Schneider, Erin F. DiMauro
  • Soluble intein fusion proteins and methods for purifying biomolecules
    Patent number: 11926854
    Abstract: The present invention relates to fusion proteins comprising an N-intein polypeptide and an N-intein solubilization partner, and affinity chromatography matrices comprising such fusion proteins, as well as methods of using same.
    Type: Grant
    Filed: April 13, 2022
    Date of Patent: March 12, 2024
    Assignee: Merck Patent GmbH
    Inventors: Martin Zillmann, Joe Orlando
  • Tablet formulation for CGRP active compounds
    Patent number: 11925709
    Abstract: The present invention is directed to compositions comprising an extrudate or solid solution of a compound, or a salt thereof, of Formula I (API): wherein “Ra” is independently —H or —F, in a water-soluble polymer matrix which further comprises a disintegration system allowing a tablet made therefrom to rapidly disintegrate in the environment in which the API is to be released.
    Type: Grant
    Filed: December 3, 2020
    Date of Patent: March 12, 2024
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Mary Ann Johnson, Leonardo Resende Allain, W. Mark Eickhoff, Craig B. Ikeda, Chad D. Brown, Francis J. Flanagan, Jr., Rebecca Nofsinger, Melanie Marota, Lisa Lupton, Paresh B. Patel, Hanmi Xi, Wei Xu
  • Crystalline salts of 5-methyl-(6S)-tetrahydrofolic acid and l-leucine ethyl ester
    Patent number: 11925644
    Abstract: The present invention refers to a crystalline salt comprising 5-methyl-(6S)-tetrahydrofolic acid L-leucine ethyl ester wherein the molar ratio of 5-methyl-(6S)-tetrahydrofolic acid and L-leucine ethyl ester is from 1:0.3 to 1:3.0 (in mol/mol) and/or hydrates and/or solvates thereof as well as to a process of obtaining the same.
    Type: Grant
    Filed: July 2, 2019
    Date of Patent: March 12, 2024
    Assignee: MERCK PATENT GMBH
    Inventors: Rudolf Moser, Viola Groehn, Ruth Boehni Stamm, Fritz Blatter, Martin Szelagiewicz